RxDoctor Payments Data

Xaje Hasanaj, MD

Internal Medicine · Eden, NCNPI 1003876871

Payments from drug & device makers

$441in general payments, 2019–2025

Across 32 payments — averaging $13.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$173
  • GSK$87
  • AstraZeneca$77
  • Astellas Pharma US Inc$38
  • AbbVie$28
  • Circassia Inc.$27
  • plus $12 from 1 others

What the payments were for

  • Food & beverage$42997%
  • Education$123%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk18$173
GSK4$87
AstraZeneca4$77
Astellas Pharma US Inc2$38
AbbVie1$28
Circassia Inc.2$27
Impel Pharmaceuticals Inc.1$12

How this compares

$441 in reported general payments places this provider in the 60th percentile of 3,302 internal medicine providers in North Carolina.

See all internal medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$132,845
Medicare patients
288
Services billed
1,854

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin384$411,109
EliquisApixaban416$352,275
OzempicSemaglutide262$287,087
Trelegy ElliptaFluticasone/Umeclidin/Vilanter160$150,653
TrulicityDulaglutide90$96,575
FarxigaDapagliflozin Propanediol81$94,122
MounjaroTirzepatide67$80,264
JanuviaSitagliptin Phosphate71$79,528
XareltoRivaroxaban48$69,976
LinzessLinaclotide70$58,906
EntrestoSacubitril/Valsartan41$49,524
CreonLipase/Protease/Amylase30$38,520
MyrbetriqMirabegron49$36,613
Lantus SolostarInsulin Glargine,hum.Rec.Anlog285$36,540
Tresiba Flextouch U-100Insulin Degludec69$34,888

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$173$310,724284 claims
GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta$87$179,632218 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort, Brilinta$77$156,922180 claims
AbbVieLinzess, Creon$28$97,426100 claims
Astellas Pharma US IncMyrbetriq$38$36,61349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 3,302 internal medicine providers in North Carolina.

Other internal medicine in Eden

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →